id: interpretation_services_availability_to_alcohol_consumption_reduction
name: Interpretation Services Availability â†’ Reduction in Alcohol Consumption Frequency
from_node:
  node_id: interpretation_services_availability
  node_name: Interpretation Services Availability
  _original_id: naltrexone_availability
to_node:
  node_id: alcohol_consumption_reduction
  node_name: Reduction in Alcohol Consumption Frequency
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Naltrexone acts as an opioid antagonist blocking endogenous opioid receptors
  involved in alcohol reward pathways'
- 'Step 2: Blockade of mu-opioid receptors reduces the reinforcing effects and subjective
  rewarding properties of alcohol'
- 'Step 3: Diminished reward and reinforcement from alcohol consumption leads to decreased
  motivation to drink'
- 'Step 4: Reduced drinking frequency and heavy drinking episodes occur when medication
  is consistently available and taken'
evidence:
  quality_rating: B
  n_studies: 3
  primary_citation: 'Henry R Kranzler and Emily E Hartwell 2023. "Medications for
    treating alcohol use disorder: A narrative review.." *Alcohol, clinical & experimental
    research*. https://doi.org/10.1111/acer.15118'
last_updated: '2025-12-02'
version: '1.0'
llm_metadata:
  extracted_by: claude-sonnet-4-5-20250929
  extraction_date: '2025-12-02T18:12:06.669173'
  batch_id: msgbatch_01AKnPJgzm7Fk9qubgAz9GaD
moderators:
- name: medication_formulation
  direction: strengthens
  strength: moderate
  description: Both oral naltrexone and extended-release naltrexone formulations show
    effectiveness, with extended-release potentially improving adherence
_source_file: /Users/mauriceelhelou/Library/CloudStorage/OneDrive-HarvardUniversity/New
  folder (2)/healthsystems/mechanism-bank/mechanisms/healthcare_access/naltrexone_availability_to_alcohol_consumption_reduction.yaml
_category: healthcare_access
